AllVascular is pleased to announce that is has been provided with $2.4m from NSW Health to accelerate the commercialisation of its lead product, the AVAS®- Arterial Access System.
The AVAS® has been used in the treatment of patients with unresectable secondary colorectal liver metastases. The results to date have been very promising, with over 60% of patients treated demonstrating clinical benefits. These have included patients that have survived for more than 5 years post treatment, which was well beyond expectations.
AllVascular applied for the funding from NSW Health as part of the Medical Devices Fund(MDF) which is run annually and is designed to encourage and support the development and commercialisation of medical technologies in NSW. Due to the value of the grant the process is competitive and highly sought after. The submissions are reviewed by an expert panel of leading NSW clinicians and experts in commercialisation chaired by Professor Durrant-Whyte (Chief Scientist and Engineer, NSW).
AllVascular is delighted with the support received from NSW Health which provides funding and access to networks facilitated by the Medical Devices Fund Expert Panel and NSW Health.